Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN versus XACIATO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN versus XACIATO.
Clindamycin vs XACIATO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing peptide bond formation.
150-450 mg orally every 6 hours; 600 mg to 1.2 g intravenously every 6-8 hours; maximum 4.8 g/day IV.
Administer one vaginal gel (50 mg clindamycin) intravaginally as a single dose.
None Documented
None Documented
2.4 hours (range 1.5-5.1 hours) in adults with normal renal function; prolonged in severe hepatic impairment.
Clinical Note
moderateClindamycin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Clotrimazole
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. Half-life may be prolonged in patients with severe hepatic impairment or neonates.
Approximately 10% of active drug and 90% as inactive metabolites via renal (feces 3.6% as active, bile significant for enterohepatic circulation).
Clindamycin is primarily excreted via bile (approximately 85% of the dose as metabolites and parent drug) and feces (10%), with renal excretion accounting for less than 10%.
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic
"The metabolism of Clotrimazole can be decreased when combined with Clindamycin."